975 results on '"Dombret, H."'
Search Results
2. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.
3. Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia
4. Correction to: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality
5. Copy-number analysis identified new prognostic marker in acute myeloid leukemia
6. TCRα rearrangements identify a subgroup of NKL-deregulated adult T-ALLs associated with favorable outcome
7. MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children’s Oncology Group Study
8. P498: CLINICAL AND BIOLOGICAL MARKERS ASSOCIATED WITH LONG-TERM SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION AFTER CHEMOTHERAPY IN THE QUAZAR AML-001 TRIAL OF ORAL AZACITIDINE
9. P374: BLINATUMOMAB AS CONSOLIDATION FOR ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA. A REAL-WORLD STUDY
10. PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
11. S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML
12. S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE
13. P404: PROGNOSTIC IMPACT OF CEBPA-MUTATIONAL SUBGROUPS IN ADULT AML – RESULTS OF A LARGE METAANALYSIS IN MORE THAN 1000 CEBPA-MUTANT PATIENTS
14. Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
15. PB1762: ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed philadelphia chromosome–positive (ph+) acute lymphoblastic leukemia (all): phallcon study
16. Autologous Stem Cell Transplantation in Acute Promyelocytic Leukemia Patients Achieving a Second Complete Remission
17. HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM
18. Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia
19. Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML
20. Growth Factors in Elderly Patients with Acute Myeloid Leukemia
21. Clinical Results of All Trans Retinoic Acid : A Targeted Drug for Differentiation Treatment in Acute Promyelocytic Leukemia
22. Adult Acute Lymphoblastic Leukemia — Results of the French AALL 87 Protocol with Different Strategies of Postremission Therapy
23. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients
24. Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS
25. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
26. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL
27. Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL
28. ALL Transretinoic Acid Followed by Intensive Chemotherapy in Newly Diagnosed Acute Promyelocytic Leukemia: A Pilot Study on 27 Cases
29. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia
30. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
31. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
32. Ponatinib Versus Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): PhALLCON Study
33. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
34. Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial
35. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
36. Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML
37. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association
38. Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia
39. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide
40. Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL
41. Optimized gene transfer into human primary leukemic T cell with NOD-SCID/leukemia-initiating cell activity
42. Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008
43. PML–RARα ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL
44. PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study
45. Outbreak in a haematology unit involving an unusual strain of glycopeptide-resistant Enterococcus faecium carrying both vanA and vanB genes
46. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
47. Traitement des leucémies aiguës promyélocytaires de l’adulte
48. In vivo selection of a complex mutant TEM (CMT) from an inhibitor-resistant TEM (IRT) during ceftazidime therapy
49. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial
50. Effect of priming with granulocyte–macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.